Glaxosmithkline Share News (GSK)

Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal

Gilead challenges GSK with strong HIV drug data

LONDON, Feb 14 (Reuters) - Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir. Gilead's bictegravir, another so-called integrase inhibitor drug

GSK upbeat on new HIV drug test results

(ShareCast News) - GlaxoSmithKline announced on Tuesday that its majority-owned specialist HIV company ViiV Healthcare, which was established with Pfizer and Shionogi as shareholders, had released detailed study results from one of its phase III programme. The FTSE 100 drugmaker said the specific pr

BROKER RATINGS SUMMARY: Morgan Stanley Raises AB Foods To Overweight

Monday broker round-up

(ShareCast News) - Berkeley Group: Barclays reiterates Equal Weight with a target price of 3175p. Flybe Group: HSBC reiterates Buy with a target price of 55p. Esure Group: Berenberg maintains Sell with a target price of 193p. Berendsen: Citigroup reiterates Neutral with a target price of 930p. Sm

GlaxoSmithKline and Gilead to face off at HIV meeting next week

By Ben Hirschler LONDON, Feb 8 (Reuters) - GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle. Most attention is focused on Gilead's next-generation drug bictegr

UPDATE 1-Weak pound buoys GSK but drugmaker warns on 2017 generic threat

* 2017 core EPS seen flat-lower if mid-year generic Advair * Current exchange rates would lift 2017 sterling EPS 9 pct * Q4 2016 core EPS 26.1 pence vs consensus forecast 25.0p (Adds CEO comments, shares, background on new CEO) By Ben Hirschler LONDON, Feb 8 (Reuters) -

Weak pound buoys GSK but drugmaker warns on 2017 generic threat

LONDON, Feb 8 (Reuters) - GlaxoSmithKline sales and profits jumped in the fourth quarter, helped by falling sterling, but the drugmaker cautioned profit growth could be impacted in 2017 by generic competition to its top-selling lung drug Advair. Outgoing Chief Executive Andrew Witty, presen

GlaxoSmithKline hits targets, earnings could slip due to generic rival

(ShareCast News) - GlaxoSmithKline hit its full year earnings target on Wednesday but said growth in 2017 could be severely hampered by the looming prospect of generic competition to its key Advair respiratory drug. The group said US sales of Advair could decline by as much as 45% to £1bn at constan

New GlaxoSmithKline CEO prepares for R&D choices, potential deals

* Walmsley takes over April 1 as generic Advair threat looms * 2017 outlook likely to incorporate Advair risks * Options for new CEO include deals and drug R&D choices By Ben Hirschler LONDON, Feb 6 (Reuters) - Emma Walmsley, GlaxoSmithKline's incoming CEO, will take over

Sunday share tips: GlaxoSmithKline, Low&Bonar

(ShareCast News) - GlaxoSmithKline chief Sir Andrew Witty will leave on a high note, leaving the company he joined in 1985 on a solid footing, and the outlook is still positive under incoming head Emma Walmsley, The Sunday Times´s Peter Evans said in his Inside the City column. A year and a half ago

As Teva wins US approval for GSK Advair copy, main fight yet to come

* Teva's Advair copy not substitutable and only for asthma * Substitutable generics could be approved in March and May By Ben Hirschler LONDON, Jan 30 (Reuters) - Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline's best-selling Adv

UPDATE 1-Danish drugmaker Novo Nordisk bets $145 mln on post-Brexit UK science

* New Oxford research centre focused on type 2 diabetes * Novo says Brexit unfortunate but UK science still a lure * Government welcomes "vote of confidence" in UK (Adds comment from minister and Novo chief science officer) By Ben Hirschler LONDON, Jan 30 (Reuters) - Nov

Friday broker round-up

(ShareCast News) - Whitbread: Barclays upgrades to Equal Weight with target price of 4150p. Inmarsat: Deutsche Bank reiterates Buy with a target price of 1020p. Halfords Group: HSBC reiterates Buy with a target price of 415p. Pets at Home: HSBC downgrades to Hold with a target price of 230p. Nati

BROKER RATINGS SUMMARY: Exane BNP Cuts Sainsbury's And Tesco